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ATPP2X1 receptors are expressed in arteries and blood platelets, play an important role in the cardiovascular
system, and their activity can be potentiated following stimulation of Gq coupled receptors or phorbol ester
treatment. The contribution of the intracellular carboxy terminus of the P2X1 receptor to this regulation was
determined using over-expression of the C terminus and a mutagenesis based approach on recombinant
receptors expressed in Xenopus oocytes. PMA induced potentiation of P2X1 receptor currents (~125% above
control) was abolished following over-expression of the intracellular carboxy terminus of the P2X1 receptor.
To determine the molecular basis of regulation by the carboxy terminus a series of individual cysteine point
mutations between His355 and Tyr370 was characterized. PMA potentiation was abolished for the P2X1
receptor mutants H355C, P358C, Y363C, K367C, F368C, K369C and Y370C. When these mutations were
introduced into the carboxy terminus fragment the inhibitory effect was absent only for P358C, K367C and
Y370C mutants. These results suggest that residues Pro358, Lys367 and Tyr370 are involved in the sequestering
effect of the carboxy terminal fragment and indicate they are directly involved in modulation of the receptor
by binding to a regulatory factor. The other mutants that abolished the PMA effect when introduced into the
P2X1 receptor are likely to be involved in transduction of the regulatory event. These studies highlight the
importance of the carboxy terminus in determining the properties and regulation of the P2X1 receptor and
suggest that the intracellular terminal regions of the receptor close to the transmembrane segments interact.: +44 116 252 5045.
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ATP gated P2X receptors comprise a distinct family of ion channels
with two transmembrane segments, intracellular amino and carboxy
termini and a large extracellular ligand binding loop (Young, 2009).
Seven human P2X receptor subunits have been identiﬁed (P2X1–7)
and these form functional homo- and hetero-trimeric receptors with a
range of properties (for review see (North, 2002)). The P2X1 receptor
is expressed in smooth muscle and contributes to neuronal control of
the vas deferens (Mulryan et al., 2000), arteries (Vial and Evans, 2002)
and the bladder (Vial and Evans, 2000). In addition, the P2X1 receptor
is expressed by platelets (MacKenzie et al., 1996). Transgenic studies
showed that P2X1 receptors on platelets do not contribute to normal
bleeding but play a signiﬁcant role in thromboembolism models
(P2X1 reduction was protective (Hechler et al., 2003) and over-
expression of P2X1 receptors increased mortality (Oury et al., 2003)).
Regulation of P2X1 receptor activity may therefore play an important
role in a variety of physiological processes.P2X1 receptors are co-expressed with G-protein coupled receptors
in many tissues. For example, with ADP-sensitive P2Y1 G-protein
coupled receptors on platelets (Gachet, 2006) and with ATP/UTP-
sensitive P2Y2 G-protein coupled receptors on arterial smooth muscle
(Ralevic and Burnstock, 1998). Activation of Gq coupled G-protein
coupled receptors potentiated P2X1 receptor responses in arteries
(Ase et al., 2005; La and Rand, 1993), as well as recombinant systems
(Ase et al., 2005; Vial et al., 2004b), and provides a mechanism for ﬁne
tuning of responses. These effects are mimicked by the phorbol ester
phorbol-12-myristate-13-acetate (PMA) and are dependent on
activation of staurosporine sensitive protein kinases (Vial et al.,
2004b;Wen and Evans, 2009). However, the lack of effect of mutation
of the conserved protein kinase C site in the intracellular amino
terminus of the P2X1 receptor on PMA or G-protein coupled receptor
regulation, coupled with the lack of changes in the phosphorylation
status of the P2X1 receptor following treatment suggests that the
regulation occurs through effects on an interacting regulatory protein
(Vial et al., 2004b). We have shown that residues in the intracellular
amino terminus close to the ﬁrst transmembrane segment (TM1) play
an important role in P2X1 receptor regulation by PMA and Gq coupled
receptors (Wen and Evans, 2009). Our recent studies have shown that
PMA treatment also leads to an increase in P2X1 receptor mobility
(Lalo et al., 2010). The carboxy terminus of P2X receptor contains a
conserved trafﬁcking motif YXXXK (Chaumont et al., 2004) and this
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regulation of the receptor. In this study we have used over-expression
of the intracellular C terminus and site directed mutagenesis based
approach to demonstrate for the ﬁrst time that the C terminal
contributes directly to PMA and Gq coupled G-protein coupled
receptor regulation of P2X1 receptors.2. Materials and methods
2.1. Intracellular C terminus fragment construction
The carboxy terminal sequence (Leu353–Stop400) of the human
P2X1 receptor was ampliﬁed from a pcDNA 3.0 vector containing the
human P2X1 receptor cDNA by PCR (Techne Genius thermocycler,
BioTAQ™DNA polymerase, Bioline, U.K.). Start and stop codons at the
ends, as well as restriction sites EcoRI and HindIII, were introduced
using primers. The sequence was ligated into the plasmid pcDNA3.0
using these two restriction sites at 14 °C overnight (T4 DNA ligase,
New England Biolabs® Inc.).2.2. Site-directed mutagenesis
Pointmutationswere introduced into the human P2X1 plasmid or the
C terminal fragment construct using the QuikChange™ mutagenesis kit
(Stratagene, Amsterdam, Netherlands) according to the manufacturer's
instructions as described previously (Ennion et al., 2000) and conﬁrmed
by DNA sequencing (Automated ABI Sequencing Service, Leicester
University, Leicester, U.K.).2.3. Expression in Xenopus laevis oocytes
The human mGlu1α receptor was a gift from Professor S. R. Nahorski
(University of Leicester, Leicester, U.K.). pcDNA3.1 vectors (Invitrogen,
Paisley, U.K.) containing either P2X1 mutant or wild type P2X1, mGlu1α
receptors or theC-terminimini-genewere linearized. Sense-strandcRNAs
were generated from these linearized plasmids with the T7 mMessage
mMachine™ kit (Ambion (Europe), Huntingdon, Cambs., U.K.). Xenopus
laevisoocytes, stageV,werepreparedbyenzymatic treatment followedby
manual defoliculation (Ennion et al., 2000). 50 nl of mRNA (1 μg/μl) was
injected into Xenopus oocytes with an Inject+Matic microinjector
(J. Alejandro Gaby, Geneva, Switzerland). For co-injections with the
mini-gene the RNA was mixed to give 5 ng wild type P2X1+10 ng
mGlu1α receptor+35 ng C-termini mini-gene (or appropriate volume of
water was added in the absence of mini-gene) and injected in a 50 nl
volume. Cells weremaintained at 18 °C in ND96 buffer (concentrations in
mM;96NaCl, 2KCl, 1.8CaCl2, 1MgCl2, 5 sodiumpyruvateand5HEPES, pH
7.5)with50 μg/mlgentamicinandwereused for recordingafter 2–6 days.2.4. Electrophysiological recordings
Two-electrode voltage clamp was used to record ATP (Mg salt;
Sigma, Poole, UK) evoked currents as described previously (Ennion
et al., 2000). ATP was applied with a fast-ﬂow U-tube perfusion
system and applications were separated by 5 min to allow recovery
from desensitization. For oocytes pre-treated with PMA, 100 nM PMA
was made in ND96 solution and the oocyteswere pre-incubated in the
PMA solution for 10 minutes at room temperature immediately before
recording. Comparisons were made between groups of control
untreated oocytes and those exposed to PMA. When looking at the
potentiation of the P2X1 receptor, glutamate (100 μM) was bath-
perfused for 5 min between ATP applications as described previously
(Vial et al., 2004a,b).2.5. Western blotting
The total and surface expression levels of P2X1 receptors were
estimated by Western blotting as described previously (Ennion et al.,
2000).
2.6. Data analysis
Data are shown as mean±S.E.M. Signiﬁcant differences between
the means compared to wild type were calculated by one-way
ANOVA, followed by Dunnett's test for comparisons of individual
mutants against control using the GraphPad Prism 5 for Windows
(GraphPad Software, San Diego, CA). Student's t test were also used
where appropriate and considered to be signiﬁcant when Pb0.05. n
corresponds to the number of oocytes tested for electrophysiological
data.
3. Results
3.1. The C terminus of the P2X1 receptor is involved in PMA and G-protein
coupled receptor regulation
We have previously shown that staurosporine sensitive protein
kinases are involved in the regulation of P2X1 receptors by PMA and
stimulationofmGlu1α receptors (Vial et al., 2004b;WenandEvans, 2009).
To determine whether the intracellular C terminus plays a role in this
regulation of the P2X1 receptorwe tested the effects of over-expressionof
the intracellular C terminus. If the C terminus is involved in regulation
over-expression of this region would be expected to interfere with the
modulation of the full length wild type receptor. The wild type P2X1
receptor was co-expressedwithmGlu1α receptors and the P2X1 receptor
mini-gene at a ratio of 1:2:7. Over-expression of the C terminus had no
effect on P2X1 receptor currents (peak current amplitudes to 100 μMATP
of −6983±340 nA, n=5 for control and −6959±626 nA, n=7 for
carboxyl terminus over-expression), or the amplitude of glutamate
evoked chloride currents (to 100 μM glutamate of −5442±777 nA,
n=5 for control, and−5511±1178 nA,n=7 for carboxy terminus over-
expression) demonstrating that over-expression of the C terminus does
not affect P2X1 or mGlu1α receptor expression, or activation. Treatment
with either PMA (100 nM) or glutamate (100 μM, for 5 min before the
application of ATP) potentiated P2X1 receptor currents as reported
previously (Vial et al., 2004b; Wen and Evans, 2009). However over-
expression of the C terminus reduced potentiation by PMA (from135.3±
13.0%, n=5 to−6.89±9.08%, n=15, ***Pb0.001) and mGlu1α receptor
stimulation (from 54.4±3.0%, n=5 to 30.1±2.2%, n=7, ***Pb0.001)
(Fig. 1). These results suggest that the C terminus is involved in kinase
regulation of the P2X1 receptor.
3.2. Effects of cysteine mutations in the C terminus of P2X1 receptor
properties
The effects of PMA on P2X1 receptor mobility (Lalo et al., 2010)
suggest that the C terminal trafﬁcking motif may be involved in
regulation. We therefore generated a series of 16 cysteine point
mutants (H355C to Y370C) that encompass the region between the
end of the second transmembrane segment (TM2) and after the
YXXXK trafﬁcking motif. A transient inward current was evoked
during the continued presence of ATP (100 μM, a maximal concen-
tration) at wild type P2X1 receptors (−6442±211 nA, n=15). Peak
current amplitudes were unaffected for 7 of the mutants, slightly
potentiated by ~20% for L357C, reduced by ~30−80% for 7 mutants,
and reduced by N98% for Y363C (Fig. 2A,B). The decrease in peak
current is unlikely to result from a major reduction in ATP sensitivity
as increasing the concentration of ATP had no effect on peak current
amplitude. To investigate whether the reduced current of the mutants
resulted from decreased surface expression a sulfo-NHS-LC
Fig. 1. PMA and mGlu1α receptor evoked potentiation of P2X1 receptors is blocked by
over-expression of the intracellular C terminus. The carboxy terminus of the P2X1
receptor was co-expressed with wild type P2X1 and mGlu1α receptors in Xenopus
oocytes. (A) Upper left panels show representative currents evoked by a maximal
concentration of ATP (100 μM, indicated by bar) at control oocytes (wild type P2X1) and
those following 10 min incubation with PMA (100 nM). Right upper panels show the
effects of over-expression of the interacellular carboxy terminus on the effects of PMA.
The bar chart shows summary data, n=5–15. (B) Upper panels show sample traces for
a given oocyte co-expressing P2X1 and mGlu1α receptors (left) or P2X1 receptors,
mGlu1α receptors and the P2X1 receptor carboxy terminal fragment (right traces).
Responses to a maximal concentration of ATP (100 μM, indicated by bar) are shown
before and after the application of glutamate (100 μM). Glutamate evoked an inward
calcium activated chloride current and potentiated subsequent ATP evoked responses.
This potentiation was reduced by co-expression of the P2X1 receptor C terminal mini-
gene. The bar chart shows a summary of the data, n=5–7. *** Pb0.001.
Fig. 2. Properties of individual cysteine point mutations of the C terminus. (A) ATP
(100 μM, application period indicated by bar) evoked rapidly desensitising currents at
wild type P2X1 receptors. Cysteine mutation had no effect at the Q365C mutant but
responses were reduced in amplitude by ~50% for R360C and by N98% for Y363C. (B)
Peak current amplitudes of ATP (100 μM) evoked currents from wild type (WT) and
cysteine mutant P2X1 receptors, * Pb0.05, *** pb0.001. (n=4–18). (C) Total and
surface expression levels of wild type and mutant P2X1 receptors with reduced peak
current amplitudes are shown.
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receptors expressed on the surface of oocytes. Total and surface
expression levels were visualized by Western blotting. The bands for
the P2X1 receptors were revealed as monomers of ~55 kDa. Surface
and total P2X1 receptor protein levels were comparable to wild type
receptors for 6 of the 8 mutants with reduced peak currents (Fig. 2C).For Y363C the peak current was reduced by N98% but there was no
effect on the surface expression of the receptor indicating that this
residue is likely to play an important role in the activation/gating of
the receptor. Reduction in surface expression (N50%) was observed at
Y362C and K367C mutants suggesting these are important for protein
trafﬁcking. These results highlight the contribution of the C terminus
to the expression and activation of P2X1 receptors.
3.3. Contribution of C terminal residues to PMA and G-protein coupled
receptor regulation
Treatment with PMA (100 nM) evoked a similar potentiation to
that recorded for P2X1 receptors (116.5±14.5%, n=11) for the
mutants I356C, L357C, K359C, R360C, H361C, Y362C, K364C, Q365C
and K366C indicating that these residues do not play an essential role
in PMA regulation. In contrast, potentiation was abolished for the
mutants P358C, Y363C, K367C, F368C, K369C and Y370C. P2X1
receptor currents were inhibited by ~80% for the mutant H355C,
(Fig. 3, ***Pb0.001). Similar reductions in mGlu1α receptor evoked
potentiation were also seen for these mutants (data not shown).
These results show that individual residues close to the second
transmembrane segment, and around the YXXXK protein trafﬁcking
motif, are involved in P2X1 receptor regulation.
Over-expression of the C terminus abolished PMA regulation and
this could result from sequestering of a regulatory interacting protein.
This is consistent with our previous studies that suggested that
protein kinase mediated regulation of the receptor is likely to be
through phosphorylation of an interacting protein (Vial et al., 2004b).
This could involve two steps, ﬁrstly the binding of the interacting
Fig. 3. Effects of cysteine mutations in the carboxy terminus of P2X1 receptors on PMA
potentiation. (A) Representative traces of ATP evoked currents (100 μM, application
indicated by bar) from oocytes under control conditions and following treatment with
PMA (100 nM) for wild type (WT) andmutants H355C, I356C and K367C. (B) Summary
of the percentage change in peak current amplitude to ATP following PMA treatment for
P2X1 receptor cysteine mutants (n=4–18). (C) Effects of cysteine mutations that
reduced PMA potentiation when introduced into the P2X1 receptor when introduced
into the C terminal fragment. Cysteine mutations P358C, K367C and Y370C abolished
the inhibitory effect of the C terminal fragment on PMA regulation. (n=5–15).
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effects of the phosphorylated protein to the increase in P2X1 receptor
responsiveness. It is possible that different amino acids could be
involved in the binding of the interacting protein and the subsequent
transduction event. If this is the case mutation of residues involved in
binding the interacting protein should abolish the sequestering effect
of over-expression of the C terminal fragment but residues involved in
transduction would have no effect on the effectiveness of the
fragment. Therefore the cysteine mutants that inhibited the PMA
effect were introduced individually into the C terminal fragment and
tested (Fig. 3C). Over-expression of C terminal fragments incorporatingthe mutants H355C, Y363C, F368C and K369C still inhibited the PMA
potentiation.HoweverC terminal fragmentswitheither theP358C,K367C
or Y370C mutation had no effect on PMA potentiation. These results
suggest that residues P358, K367 and Y370 are involved in direct
interaction with a regulatory factor and residues H355, Y363, F368 and
K369 are involved in transduction of the regulatory event.
4. Discussion
Thepresent study shows that theC terminusplays an important role in
the regulation of P2X1 receptor expression, gating, and regulationby PMA
andGqG-protein coupled receptors. Pointmutations in the region close to
TM2 incorporating a conserved trafﬁckingmotif can lead to a reduction in
P2X1 receptor responsiveness. For the H355C, K359C, R360C, H361C,
Y363C and F386C mutants surface expression of these mutants was
unaffected and it is likely that the reduction in responsiveness resulted
from a reluctance of the ATP bound receptor to open i.e. an effect on
channel gating. This is consistentwithprevious studies showing that theC
terminus contributes to shaping the time-course of P2X receptor currents
(Brandle et al., 1997; Fountain andNorth, 2006; Smith et al., 1999). For the
mutants Y362C and K367C the ~50% reduction in ATP evoked currents
was mirrored by an equivalent reduction in their surface expression. At
ﬁrst glance this appears consistent with the role tyrosine and lysine
residues in the YXXXK conserved trafﬁcking motif identiﬁed in P2X2-6
receptors (Chaumont et al., 2004). However if thiswere the case it should
be Y363C that had reduced surface expression; this mutant showed a
N98% reduction in evoked currents but no change in surface expression.
These results suggest that at the P2X1 receptor there is some ﬂexibility in
the trafﬁcking motif and that it is a YXXXXK and not a YXXXK motif that
regulates their surface expression.
Over-expression of protein fragments can interfere with receptor
regulation. The reduction of PMA and G-protein coupled receptor
potentiation of the P2X1 receptor following over expression of the C
terminal domain identiﬁed the importance of this region in channel
regulation. We and others have previously shown that P2X1 receptor
potentiation by PMA and G-protein coupled receptors was mediated
by a novel serine/threonine protein kinase C isoform (Ase et al., 2005;
Wen and Evans, 2009). There are no consensus sites for protein kinase
C phosphorylation in the carboxy terminus. However the cysteine
mutations H355, P358, Y363C and K367-Y370 abolished the poten-
tiation by PMA and this suggests the receptor is regulated through an
indirect mechanism. This further supports previous studies demon-
strating that removal of the consensus sequence for PKC phosphor-
ylation in the amino terminus has no effect on potentiation, and that a
change in P2X1 receptor phosphorylation could not be detected
following PMA treatment (Vial et al., 2004b), leading to the conclusion
that protein kinase C regulates the P2X1 receptor through phosphor-
ylation of an interacting regulatory protein (Vial et al., 2004a; Wen
and Evans, 2009). By combining over-expression of the intracellular C
terminal fragment and mutagenesis approaches we were able to
characterise these cysteine mutations into those that had no effect on
(H355C, Y363C, F368C and K369C), or abolished the inhibitory effects
of the C terminal fragment (P358C, K367C and Y370C). These results
highlight the importance of residues P358, K367 and Y370 in the
sequestering effects of the C terminal fragment and suggest that they
may interact directly with the regulatory protein. In contrast the
abolition of PMA and G-protein coupled receptor regulation by
mutations H355C, Y363C, F368C and K369C when they were
introduced into the full length P2X1 receptor and but not the C
terminal fragment suggests that these residues are not involved in
direct interaction with the regulatory factor but are essential for
transduction of the change evoked by the regulatory factor.
We have previously shown that the amino terminus of the P2X1
receptor also contributes to PMA and G-protein coupled receptor
mediated potentiation of the receptor (Wen and Evans, 2009). This
work, like the current study, also identiﬁed residues thatwereproposed to
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transduction of the regulatory event. This raises the possibility that the
intracellular amino and carboxy termini may interact to regulate the
receptor. Structural information on this interaction is not currently
available as the intracellular domains were truncated to facilitate the
crystalization of the zebra-ﬁsh P2X4 receptor (Kawate et al., 2009).
However a homologymodel of the P2X1 receptor based on the zebra-ﬁsh
P2X4 receptor structure predicts that residues G30 and H355 are ~14
angstrom apart. Bio-informatic algorithms predict that part of the amino
terminus before TM1 forms a beta sheet and a region of the carboxy
terminus after TM2 may form as an alpha helix ((McGufﬁn et al., 2000).
Based on this informationwe canmap themutagenesis results of this, and
our previous study on PMA regulation (Wen and Evans, 2009) to produce
a model of the intracellular domains (Fig. 4). These results demonstrate
that residues involved in PMA regulation are clustered. It is interesting
that those amino acids that when mutated to cysteine and abolish PMA
regulationwhen introduced to the full lengthP2Xreceptor, andnegate the
actionof the aminoor carboxy terminimini-genes, are located equidistant
(11–14 and 14–17 residues) from the TMs. It is tempting to speculate that
these residues, involved in the sequestering action of themini-genes,may
interact to form a pocket/environment for the binding of an interacting
protein and regulation by PMA. Interestingly this brings together the two
intracellular regions (TXR/K in the amino terminus and YXXXK in the
carboxy terminus) that are conserved throughout the P2X receptor
family. Indeed, where tested, other P2X receptor subtypes have also
been shown to be regulated by PMA/Gq coupled G-protein coupled
receptors (Boue-Grabot et al., 2000; Paukert et al., 2001). This suggests
that this region may form a conserved pocket for P2X receptor
regulation. The region within 1–4 amino acids of the TM domains also
comprises a cluster of residues that regulate PMA action through an
effect when introduced in the P2X1 receptor but not the C terminal
fragment; indicative of an effect on transduction of the regulatory event.
There is one exception; P358C. However proline is a unique amino acid
that can introduce kinks in proteins andmutation to cysteinemay haveFig. 4.Model of the amino and carboxy termini of the P2X1 receptor showing residues
involved in PMA regulation. The effects of cysteine mutants of residues Y16-G30 (from
(Wen and Evans, 2009)) and H355-Y370 on PMA regulation are shown. Residues in
back abolished PMA regulation when introduced into the P2X1 receptor and removed
the inhibitory effect of the corresponding mini-gene (involved in sequestering effect of
mini-gene and predicted interaction with regulatory protein). Residues in grey are
those that when mutated in the P2X1 receptor abolished PMA regulation but did not
reduce the inhibitory effect when introduced into the C terminal fragment
(transduction effect). The transmembrane segments are shown as boxes (TM1 and
TM2). Secondary structural predictions of a beta sheet in the amino terminus and an
alpha helix in the carboxy terminus are shown, * indicates residues that are conserved
throughout the P2X receptor family and # indicates where there is a conserved positive
charge.had an adverse effect on the folding of the C terminal fragment that
could explain the reduction of effect. Overall these results suggest that
the intracellular amino and carboxy termini interact and form a binding
pocket for a regulatory factor that can potentiate P2X1 receptor
currents. This provides a mechanism for the ﬁne tuning of the
responsiveness of the P2X1 receptor in native systems by G-protein
coupled receptors, for example in arteries and platelets.
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